Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2021-03-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
关于实际控制人及其一致行动人部分股份解除质押及质押公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the actual controller and related parties of the company. It details the number of shares pledged, released, and the terms of these pledges. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledging activities, which relates to capital structure but is not a financing update per se. It is not a report or presentation but a formal disclosure of share pledge status. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-03-01 Chinese
2020年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a 2020 annual performance quick report (业绩快报) and contains preliminary financial data for the year 2020, including revenue, profit, net income, and other key financial metrics. It explicitly states that the data is preliminary and unaudited, which is typical for an earnings release or performance summary rather than a full annual report. The document length is 2245 characters, which is relatively short and consistent with a brief earnings announcement rather than a comprehensive annual report (10-K). There is no indication that this is a full audited annual report or a detailed management discussion and analysis. The document is a financial results announcement for the full year 2020, which fits the definition of an Earnings Release (ER). FY 2020
2021-02-26 Chinese
关于全资子公司获得《药品注册批件》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary receiving a drug registration approval from the National Medical Products Administration. It details the drug's basic information, its therapeutic use, the impact on the company, and risk warnings. The document is short (932 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report, management discussion, or other detailed filings. It does not contain financial data, management changes, voting results, or legal proceedings. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-02-07 Chinese
关于全资子公司获得《药品注册批件》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Huabang Life Health Co., Ltd. regarding its wholly-owned subsidiary obtaining a drug registration approval from the National Medical Products Administration. It details the drug name, registration number, intended use, and potential impact on the company. The document is short (1103 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval event. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like earnings, management changes, or capital updates.
2021-02-02 Chinese
关于控股子公司山东凯盛新材料股份有限公司在全国中小企业股份转让系统终止挂牌的公告
Delisting Announcement Classification · 100% confidence The document is an official announcement regarding the termination of listing of a subsidiary's stock on the National SME Share Transfer System. It includes references to board resolutions and regulatory approvals for delisting. The content is focused on the delisting event and related procedural disclosures, not on financial results or reports. The document length is short (986 characters) and it is a formal notice of delisting. Therefore, the appropriate classification is Delisting Announcement (DLST).
2021-01-21 Chinese
关于控股股东股份质押公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, pledge start and end dates, and other related information. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledging activity by major shareholders, which fits the category of Major Shareholding Notification (MRQ). The document length is 3082 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ.
2020-12-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.